P T Pollak

Summary

Publications

  1. ncbi request reprint Elevation of high-density lipoprotein cholesterol in humans during long-term therapy with amiodarone
    P T Pollak
    Department of Medicine, Dalhousie University, Queen Elizabeth II Health Sciences Center, Halifax, Nova Scotia, Canada
    Am J Cardiol 83:296-300, A7. 1999
  2. ncbi request reprint Quetiapine fumarate overdose: clinical and pharmacokinetic lessons from extreme conditions
    P T Pollak
    Department of Medicine, Queen Elizabeth II HSC, Dalhousie University, Halifax, Nova Scotia, Canada
    Clin Pharmacol Ther 68:92-7. 2000
  3. ncbi request reprint Determination of plasma concentrations of losartan in patients by HPLC using solid phase extraction and UV detection
    P K Yeung
    Pharmacokinetics and Metabolism Laboratory, College of Pharmacy, Faculty of Health Professions, Dalhousie University, Halifax, NS, Canada
    Int J Pharm 204:17-22. 2000
  4. ncbi request reprint Sertraline-induced hypoglycemia
    P T Pollak
    Department of Medicine, College of Pharmacy, Dalhousie University, Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada
    Ann Pharmacother 35:1371-4. 2001
  5. ncbi request reprint Therapeutically relevant blood pressure differences with two nifedipine (60 mg) osmotic delivery systems of differing design: three case reports
    P T Pollak
    Departments of Medicine, Cardiac Sciences, and Physiology and Pharmacology, University of Calgary, Calgary, Canada
    Int J Clin Pharmacol Ther 48:400-4. 2010
  6. pmc The use of amiodarone for in-hospital cardiac arrest at two tertiary care centres
    P Timothy Pollak
    Department of Medicine, Dalhousie University, Halifax, Nova Scotia
    Can J Cardiol 22:199-202. 2006
  7. ncbi request reprint Use of population modeling to define rational monitoring of amiodarone hepatic effects
    P Timothy Pollak
    Department of Medicine, Queen Elizabeth II Health Sciences Centre, Dalhousie University, Halifax, Nova Scotia, Canada
    Clin Pharmacol Ther 75:342-51. 2004
  8. ncbi request reprint Monitoring of hepatic function during amiodarone therapy
    P Timothy Pollak
    Department of Medicine, Dalhousie University, Queen Elizabeth II Health Sciences Center, Halifax, Nova Scotia, Canada
    Am J Cardiol 91:613-6. 2003
  9. ncbi request reprint Altered metabolite concentrations with amiodarone generic substitution cannot be observed without monitoring
    P T Pollak
    Dalhousie University, Queen Elizabeth II Health Sciences Centre, Halifax, Canada
    Can J Cardiol 17:1159-63. 2001
  10. ncbi request reprint Population pharmacokinetics of long-term oral amiodarone therapy
    P T Pollak
    Department of Medicine Dalhousie University, Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada
    Clin Pharmacol Ther 67:642-52. 2000

Collaborators

  • M H Tan
  • P K Yeung
  • G J Smith
  • A Jamieson
  • D Fice

Detail Information

Publications10

  1. ncbi request reprint Elevation of high-density lipoprotein cholesterol in humans during long-term therapy with amiodarone
    P T Pollak
    Department of Medicine, Dalhousie University, Queen Elizabeth II Health Sciences Center, Halifax, Nova Scotia, Canada
    Am J Cardiol 83:296-300, A7. 1999
    ....
  2. ncbi request reprint Quetiapine fumarate overdose: clinical and pharmacokinetic lessons from extreme conditions
    P T Pollak
    Department of Medicine, Queen Elizabeth II HSC, Dalhousie University, Halifax, Nova Scotia, Canada
    Clin Pharmacol Ther 68:92-7. 2000
    ..Observation of an overdose situation provided a unique opportunity to define the safety, clinical effects, and pharmacokinetics of this medication more clearly...
  3. ncbi request reprint Determination of plasma concentrations of losartan in patients by HPLC using solid phase extraction and UV detection
    P K Yeung
    Pharmacokinetics and Metabolism Laboratory, College of Pharmacy, Faculty of Health Professions, Dalhousie University, Halifax, NS, Canada
    Int J Pharm 204:17-22. 2000
    ..To establish a HPLC assay for plasma losartan and its active metabolite EXP3174 to facilitate clinical pharmacokinetic studies...
  4. ncbi request reprint Sertraline-induced hypoglycemia
    P T Pollak
    Department of Medicine, College of Pharmacy, Dalhousie University, Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada
    Ann Pharmacother 35:1371-4. 2001
    ..To report a case of hypoglycemia that occurred in a patient treated with the selective serotonin-reuptake inhibitor, sertraline...
  5. ncbi request reprint Therapeutically relevant blood pressure differences with two nifedipine (60 mg) osmotic delivery systems of differing design: three case reports
    P T Pollak
    Departments of Medicine, Cardiac Sciences, and Physiology and Pharmacology, University of Calgary, Calgary, Canada
    Int J Clin Pharmacol Ther 48:400-4. 2010
    ..In at least some patients, the alternate pump technology appears less effective. This highlights the need for better bioequivalence criteria for comparing differing delivery technologies that artificially retard absorption of the drug...
  6. pmc The use of amiodarone for in-hospital cardiac arrest at two tertiary care centres
    P Timothy Pollak
    Department of Medicine, Dalhousie University, Halifax, Nova Scotia
    Can J Cardiol 22:199-202. 2006
    ..Although amiodarone significantly increases survival to hospital admission when used in resuscitation of out-of-hospital pulseless ventricular tachycardia and fibrillation, there are limited data on its utility for in-hospital arrests...
  7. ncbi request reprint Use of population modeling to define rational monitoring of amiodarone hepatic effects
    P Timothy Pollak
    Department of Medicine, Queen Elizabeth II Health Sciences Centre, Dalhousie University, Halifax, Nova Scotia, Canada
    Clin Pharmacol Ther 75:342-51. 2004
    ..Amiodarone causes hepatotoxicity in experimental models, but in humans, the relationships between drug administration, serum concentrations, markers of liver function, and how to monitor for hepatotoxicity have not been well characterized...
  8. ncbi request reprint Monitoring of hepatic function during amiodarone therapy
    P Timothy Pollak
    Department of Medicine, Dalhousie University, Queen Elizabeth II Health Sciences Center, Halifax, Nova Scotia, Canada
    Am J Cardiol 91:613-6. 2003
  9. ncbi request reprint Altered metabolite concentrations with amiodarone generic substitution cannot be observed without monitoring
    P T Pollak
    Dalhousie University, Queen Elizabeth II Health Sciences Centre, Halifax, Canada
    Can J Cardiol 17:1159-63. 2001
    ..Physicians should monitor patients for several months after a switch in amiodarone formulation is made. Regulatory criteria for bioequivalence of amiodarone need to be reconsidered...
  10. ncbi request reprint Population pharmacokinetics of long-term oral amiodarone therapy
    P T Pollak
    Department of Medicine Dalhousie University, Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada
    Clin Pharmacol Ther 67:642-52. 2000
    ..Amiodarone is an increasingly popular and uniquely effective antiarrhythmic agent for which population pharmacokinetic parameters in patients receiving long-term oral therapy have not been defined previously...